Ocular Therapeutix (NASDAQ:OCUL) Stock, Quote.Headers.trade-ideas

Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

xr:d:DAFl_HSvCpE:2,j:6755793051000407071,t:23061612

News

Intraday Update

Markets

Movers

Trading Ideas

ALUR

APLD

ASNS

BILI

DMTK

ESPR

FEMY

GRDI

HIMX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HROW

IBRX

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

KAVL

LOBO

LRHC

MBIO

MGOL

MOLN

NKLA

NLSP

NNVC

NYAX

OCUL

PACK

PRST

RELI

SLNH

SMCI

SONN

SRFM

SVMH

TBLT

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVN

VNDA

ZAPP

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

GILD

GLOB

KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday

xr:d:DAFibKzrYwA:2,j:4304114698,t:23050912

Analyst Color

Upgrades

IRTC

SWKS

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Ocular Therapeutix Inc

Oculis Holding AG

Oculus Inc

<p>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>, "Ocular", the "Company"))), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for AXPAXLI&#x2122; in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic retinopathy (NPDR), and the Company's strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).</p>


Ocular Therapeutix Showcases Progress on AXPAXLI for Wet AMD and Diabetic Retinopathy at JPM 2025

<h3>Gainers</h3>
<ul>
<li><strong>Agape ATP</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares increased by 81.0% to $2.28 during Monday's pre-market session. The company's market cap stands at $9.0 million. </li>
<li><strong>Sage Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares moved upwards by 36.93% to $7.6. The company's market cap stands at $464.9 million. </li>
<li><strong>Intra-Cellular Therapies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares rose 35.56% to $128.61. The company's market cap stands at $13.6 billion. </li>
<li><strong>GlucoTrack</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 32.73% to $0.16. The market value of their outstanding shares is at $2.4 million. </li>
<li><strong>CytoMed Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock moved upwards by 27.53% to $3.52. The market value of their outstanding shares is at $40.6 million. </li>
<li><strong>GT Biopharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares increased by 26.03% to $3.34. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Ocular Therapeutix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) stock fell 14.7% to $7.0 during Monday's pre-market session. The company's market cap stands at $1.1 billion. </li>
<li><strong>Indaptus Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares declined by 13.69% to $0.82. The market value of their outstanding shares is at $9.8 million. </li>
<li><strong>Aligos Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) shares decreased by 12.7% to $29.43. The market value of their outstanding shares is at $105.5 million. </li>
<li><strong>NovaBay Pharmaceuticals</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock fell 12.49% to $0.61. The market value of their outstanding shares is at $2.9 million. </li>
<li><strong>AirSculpt Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock declined by 12.21% to $5.25. The company's market cap stands at $303.8 million. </li>
<li><strong>NAYA Biosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock declined by 12.11% to $0.71. The market value of their outstanding shares is at $3.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AIRS

ALGS

ATPC

GCTK

GDTC

GTBP

INDP

ITCI

NAYA

SAGE

12 Health Care Stocks Moving In Monday's Pre-Market Session

<p>Across the recent three months, 4 analysts have shared their insights on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.5, with a high estimate of $22.00 and a low estimate of $14.00. This current average reflects an increase of 15.14% from the previous average price target of $14.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245224_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Ocular Therapeutix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ocular Therapeutix. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Ocular Therapeutix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ocular Therapeutix's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ocular Therapeutix analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Ocular Therapeutix: A Closer Look</h2>
<p>Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.</p>
<h3>Ocular Therapeutix: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Ocular Therapeutix showcased positive performance, achieving a revenue growth rate of <strong>2.28%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ocular Therapeutix's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-236.58%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ocular Therapeutix's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-10.0%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.24%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Ocular Therapeutix's debt-to-equity ratio is below the industry average. With a ratio of <b>0.21</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts

<p>HC Wainwright &amp; Co.  analyst Yi Chen   reiterates Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and maintains $15 price target.</p>


Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $15 Price Target

Biotech

Health Care

General

Ocular Therapeutix Announced That More Than 300 Patients Have Been Randomized In SOL-1 Phase 3 Trial For Axpaxli (Axitinib Intravitreal Implant, Or OTX-TKI) For Wet Age-related Macular Degeneration, And The Trial Is Expected To Close Randomization This Week, Topline Data Are Expected In Q4 Of 2025

<p>HC Wainwright &amp; Co.  analyst Yi Chen   maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and raises the price target from $14 to $15.</p>


HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $15

Earnings

Guidance

Ocular Therapeutix's Cash Balance Of $427.2M As Of September 30, 2024, Expected To Fund Operations Into 2028

<p>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent.  The company reported quarterly sales of $15.43 million which missed the analyst consensus estimate of $17.14 million by 10.01 percent.  This is a 2.28 percent increase over sales of $15.08 million the same period last year.</p>


Ocular Therapeutix Q3 2024 GAAP EPS $(0.22) Beats $(0.24) Estimate, Sales $15.43M Miss $17.14M Estimate

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

<p><strong>Ocular Therapeutix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Ocular Therapeutix will report an <strong>earnings per share</strong> (EPS) of $-0.24. </p>
<p>The announcement from Ocular Therapeutix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.04, leading to a 4.06% drop in the share price the following trading session.</p>
<p>Here's a look at Ocular Therapeutix's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.22</td>
<td>-0.19</td>
<td>-0.30</td>
<td>-0.29</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.26</td>
<td>-0.28</td>
<td>-0.35</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731510106_0.png" alt="eps graph" /></p>
<h3>Analysts' Perspectives on Ocular Therapeutix</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ocular Therapeutix.</p>
<p>Analysts have given Ocular Therapeutix a total of 2 ratings, with the consensus rating being Buy. The average one-year price target is $18.0, indicating a potential 69.81% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Harrow, Harmony Biosciences and Supernus Pharmaceuticals, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Harrow is favoring an Buy trajectory, with an average 1-year price target of $56.67, suggesting a potential 434.62% upside.</li>
<li>As per analysts' assessments, Harmony Biosciences is favoring an Buy trajectory, with an average 1-year price target of $52.5, suggesting a potential 395.28% upside.</li>
<li>The consensus among analysts is an Neutral trajectory for Supernus Pharmaceuticals, with an average 1-year price target of $36.0, indicating a potential 239.62% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Harrow, Harmony Biosciences and Supernus Pharmaceuticals, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular Therapeutix</td>
<td>Buy</td>
<td>8.26%</td>
<td>$14.93M</td>
<td>-11.14%</td>
</tr>
<tr>
<td>Harrow</td>
<td>Buy</td>
<td>46.22%</td>
<td>$36.40M</td>
<td>-10.87%</td>
</tr>
<tr>
<td>Harmony Biosciences</td>
<td>Buy</td>
<td>16.08%</td>
<td>$143.26M</td>
<td>8.12%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>14.17%</td>
<td>$158.11M</td>
<td>3.92%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ocular Therapeutix ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. The company's Consensus rating is not the highest among its peers.</p>
<h3>Discovering Ocular Therapeutix: A Closer Look</h3>
<p>Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.</p>
<h3>Ocular Therapeutix's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Ocular Therapeutix displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>8.26%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Ocular Therapeutix's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-266.27%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ocular Therapeutix's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-11.14%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.29%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.2</strong>, Ocular Therapeutix adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/OCUL/earnings"><strong>To track all earnings releases for Ocular Therapeutix visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Ocular Therapeutix's Future Earnings

WIIM

Ocular Therapeutix shares are trading higher after Scotiabank Initiated coverage on the stock with a Sector Outperform rating and announced a $22 price target.

<p>Scotiabank  analyst Greg Harrison   initiates coverage on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Sector Outperform rating and announces Price Target of $22.</p>


Initiation

Scotiabank Initiates Coverage On Ocular Therapeutix with Sector Outperform Rating, Announces Price Target of $22

<p>HC Wainwright &amp; Co.  analyst Yi Chen   reiterates Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and maintains $14 price target.</p>


HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target

<ul>
<li>SOL-1 is now expected to be enrolled and fully randomized by year-end 2024</li>
<li>Topline clinical data from SOL-1 are now expected in&nbsp;Q4&nbsp;2025</li>
</ul>


Ocular Therapeutix Fast-Tracks SOL-1 Registrational Trial For Wet AMD, Topline Data Expected In Late 2025

<p>Baird  analyst Colleen Kusy   maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Outperform and lowers the price target from $18 to $17.</p>


Baird Maintains Outperform on Ocular Therapeutix, Lowers Price Target to $17

Ocular Therapeutix' Cash Balance Of $459.7M As Of June 30, 2024, Expected to Fund Operations Into 2028

Ocular Therapeutix Q2 2024 GAAP EPS $(0.26) Misses $(0.22) Estimate, Sales $16.441M Beat $15.824M Estimate

Ocular Therapeutix Has Received FDA Written Response That Phase 3 Sol-r Trial Is Appropriate For Use As The Company's Second Adequate And Well Controlled Study Of Axpaxli (Axitinib Intravitreal Implant, Also Known As OTX-TKI) For Wet Age-related Macular Degeneration

<p>Analysts' ratings for Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $14.0, along with a high estimate of $22.00 and a low estimate of $7.00. This current average represents a 3.45% decrease from the previous average price target of $14.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722535538_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Ocular Therapeutix's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Tara Bancroft</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Tara Bancroft</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ocular Therapeutix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Ocular Therapeutix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ocular Therapeutix's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ocular Therapeutix analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Ocular Therapeutix</h2>
<p>Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.</p>
<h3>Ocular Therapeutix: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Ocular Therapeutix's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>10.47%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ocular Therapeutix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-438.93%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ocular Therapeutix's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-25.99%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-16.4%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.18</strong>, Ocular Therapeutix adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock

Ocular Therapeutix (OCUL) announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI, and the trial is expec...

Ocular Therapeutix announces over 300 subjects randomized in SOL-1

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report), retaining the price target of $15.00. Yi...

Promising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial Valuation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report), Baxter Inte...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Baxter International (BAX) and Ocular Therapeutix (OCUL)

Ocular Is Now Thoroughly Derisked

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report)...

Ocular Therapeutix (OCUL) Receives a Buy from Bank of America Securities

Citi initiated coverage of EyePoint (EYPT) with a Buy rating and $33 price target. The firm expects both EyePoint and competitor Ocular Therapeutix...

EyePoint initiated with a Buy at Citi

EyePoint initiated at buy by Citi on wAMD drug potential

Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company's strategic outlook for 2025 in...

Ocular Therapeutix shares SOLR-R enrollment progress, next steps AXPAXLI

Comments

Ocular Therapeutix

Ocular Therapeutix (OCUL) Forecast

Ocular Therapeutix (NASDAQ:OCUL) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga